Allergopharma

At Allergopharma, we are driven by a deep passion and unwavering commitment to advancing allergology. As a specialist in allergen immunotherapy (AIT) and a proud member of the Dermapharm Group, we are at the forefront of innovation in allergy treatment. With over 55 years of expertise, we have worked closely with leading physicians and scientists to develop safe, effective, and long-term allergy solutions. Allergopharma was among the first to prioritize both efficacy and disease modification in AIT, paving the way for groundbreaking advancements that improve patients' lives. Our dedication to scientific excellence, corporate responsibility, and patient well-being drives us to provide high-quality therapeutic options. Every day, we take bold steps toward realizing our vision: a world where allergies no longer define lives. We believe every allergy patient deserves a solution tailored to their unique needs. Our extensive portfolio includes next-generation, high-dose, hypoallergenic allergen immunotherapy (Allergoids) for pollen and mite allergies, depot AIT preparations for mite, and for rare allergies caused by molds and animal epithelia. We also offer diagnostic solutions, including skin prick and provocation tests for precise IgE-mediated allergy detection. Backed by cutting-edge process technology and scientific expertise, we continuously innovate to enhance long-term allergy treatments. Our products are available in select markets across Asia and Europe, supported by dedicated affiliates and trusted distribution partners who share our commitment to excellence. At Allergopharma, we are more than just a company—we are a driving force for change in allergy treatment. With collaboration, innovation, and determination, we are not only treating allergies—we are transforming lives and shaping a future free from allergic limitations.